TM4SF5 (Transmembrane 4 L Six Family Member 5)

Therefore, the unique features in the LEL and the N-glycosylation of TM4SF5 may contribute to dimer formation and cholesterol binding, potentially influencing regulatory roles in liver malignancy development.

Some identified genes may be the driver genes of lung adenocarcinoma and have some druggable potential. These findings provide new insights into the molecular mechanisms of lung adenocarcinoma and suggest promising targets for future diagnostic and therapeutic strategies.

Tumor tissues from liver-orthotopically xenografted mice fed a high protein diet or human liver cancer tissues showed TM4SF5-dependent macropinocytosis and NCOA3-correlated metastatic features, unlike mice fed a normal chow diet or human nontumor regions. These observations indicate that serum albumin availability to TM4SF5-positive HCC could support multifocality and intrahepatic metastasis, which may provide insights into clinical observations of multiple small tumor nodules surrounded by areas with high serum albumin levels.

In mouse xenograft models, TSI treatment abrogated HCC development by increasing the abundance and dispersion of Slamf7-positive cells in liver tissues, recapitulating the phenotype of Tm4sf5-knockout mice and indicating TSI-mediated restoration of NK cell surveillance. These findings suggest that TSIs can inhibit TM4SF5-mediated liver carcinogenesis by increasing NK cell surveillance.

These results were consistent with in vitro findings, where t Ex[miR-143] demonstrated the highest inhibition of HCT116 cell migration and invasion. These findings highlight the potential of tEx[miR-143] as an effective therapeutic strategy for colorectal cancer, demonstrating promising results in both targetability and anti-tumor effects in vitro and in vivo, warranting further investigation in clinical settings.

Our findings suggested that TM4SF5-enriched MLCSs regulate glucose catabolism by facilitating cholesterol export for mitochondrial reprogramming, presumably while hepatocellular carcinogenesis, recapitulating aspects for hepatocellular carcinoma metabolism with mitochondrial reprogramming to support biomolecule synthesis in addition to glycolytic energetics.

In addition, TM4SF5 can remodel the immune environment by interacting with immune cells during TM4SF5-mediated chronic liver diseases. Because TM4SF5 may act as an NAFLD biomarker, this review summarizes crosstalk between TM4SF5 and nutrient transporters in hepatocytes, which is related to chronic liver diseases.